Journal of Endocrinological Investigation

, Volume 15, Issue 11, pp 801–806 | Cite as

Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease

  • C. Nappi
  • Pietro Affinito
  • C. Di Carlo
  • G. Esposito
  • U. Montemagno


The clinical effectiveness and safety of vaginal micronized progesterone treatment in mastodynia were evaluated in a double-blind placebo controlled study. Eighty regularly menstruating worn-’ en affected by severe cyclical mastodynia were randomly assigned to two groups of 40 patients. One group was treated for 6 cycles from the 19th to the 25th day of the cycle with 4 g of vaginal cream containing 2.5% natural progesterone. The other group was similarly treated with placebo. The treatment was preceded by a control cycle. All patients reported every day their breast pain on a 100 mm visual linear analogue scale (VAS). The response of breast tenderness and nodularity to treatment was assessed by clinical examination. Vaginal progesterone resulted significantly more efficacious than placebo in reducing mean ratings of breast pain on VAS and mean scores of breast tenderness to touch. Success of treatment, defined as reduction greater than 50% of basal mean score of breast pain on VAS, was achieved in the 64.9% of patients treated with progesterone and in the 22.2% of patients receiving placebo (p<0.01). Conversely, at the end of treatment, the improvement in breast nodularity showed a not statistically significant difference between the two groups. No major side-effects were detected.


Mastalgia progesterone benign brest disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wisbey J.R., Kumar S., Mansel R.E., Preece P.E., Pye J.K., Hughes L.E. Natural history of breast pain. Lancet 2: 672, 1983.PubMedCrossRefGoogle Scholar
  2. 2.
    Fentiman I.S., Caleffi M., Bram K., Chandary M.A., Hayward J.L. Double blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1: 287, 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    Sitruk-Ware R., Sterkers N., Mowszowicz I., Mauvais-Jarvis P. Inadeguate corpus luteum function in women with benign breast diseases. J. Clin. Endocrinol. Metab. 44:771, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    England P.C., Skinner L.G., Cottrell K.M., Sellwood R.A. Sex hormones in breast disease. Br. J.Surg. 62:806, 1975.PubMedCrossRefGoogle Scholar
  5. 5.
    Walsh P.V., Bulbrook R.D., Stell P.M., Wang D.Y., McDicken I.W., George W.D. Serum progesterone concentration during the luteal phase in women with benign breast disease. Eur. J. Cancer. Clin. Oncol. 20:1339, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Read G.F., Bradley S.A., Wilson D.W., George W.D., Griffiths K. Evaluation of luteal-phase salivary progesterone levels in women with benign breast disease or primary breast cancer. Eur. J. Clin. Oncol. 21: 9, 1985.CrossRefGoogle Scholar
  7. 7.
    Wang D.Y., Fentiman I.S. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res. Treat. 6:5, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Kumar S., Mansel R.E., Hughes L.E., Woodhead J.S., Edwards C.A., Scanlon M.F., Newcombe R.G. Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53:1311, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Kumar S., Mansel R.E., Wilson D.W., Read G.F., Truran P.L., Hughes L.E., Griffiths K. Daily salivary progesterone levels in cyclical mastalgia patients and their controls. Br. J.Surg. 73:260, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Rannevik G., Doberl A., Gershagen S., Rasmussen T.H., Tobiassen T. Elevated serum concentrations of sex hormone binding globulin in fibrocystic breast disease. In: Angeli A., Bradlow H.L., Dogliotti L. (Eds.), Endocrinology of cystic breast disease. Raven Press, New York, 1983, p. 127.Google Scholar
  11. 11.
    Carlstrom K., Doberl A., Gershagen S., Rannevik G., Rasmussen T.H., Tobiassen T. Elevated peripheral levels of androgens and of some steroid sensitive plasma proteine in patients with severe fibrocystic breast disease. Acta Obstet. Gynecol. Scand. (Suppl.) 23:157, 1984.CrossRefGoogle Scholar
  12. 12.
    Greenblatt R.B., Nezhat C., Ben Nun I. The treatment of benign breast disease with danazol. Fertil. Steril. 34:242, 1980.PubMedGoogle Scholar
  13. 13.
    Pye J.K., Mansel R.E., Hughes L.E. Clinical experience of drug treatments for mastalgia Lancet 2: 373, 1985.PubMedCrossRefGoogle Scholar
  14. 14.
    Andrews W.C. Hormonal management of fibrocystic disease of the breast. J. Reprod. Med. 35:87, 1990.PubMedGoogle Scholar
  15. 15.
    Ricciardi I., Ianniruberto A. Tamoxifen-induced regression of benign breast lesion. Obstet. Gynecol. 54:80, 1979.PubMedCrossRefGoogle Scholar
  16. 16.
    Shaaban M.M., Morad F., Hassan A-el-R. Treatment of fibrocystic mastopathy by an anti-estrogen, tamoxifen. Int. J. Gynecol. Obstet. 73:348, 1980.Google Scholar
  17. 17.
    Mansel R.E., Preece P.E., Hughes L.E. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br. J. Surg. 65:724, 1978.PubMedCrossRefGoogle Scholar
  18. 18.
    Blichert-Toft M., Anderson A.N., Henriksen O.B., Migind T. Treatment of mastalgia with bromocriptine: a double blind cross-over study. Br. Med. J. 1: 237, 1979.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Vorherr H. Fibrocystic breast disease: Pathophysiology, pathomorphology, clinical picture and management. Am. J. Obstet. Gynecol. 154:161, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Ruf H., Codaccioni J.L., Serment H. Le norethynodrel dans le syndrome premenstruel et les dysplasies mammaires. Bull. Fed. Gynec. Obstet. Franc. 76:587, 1964.Google Scholar
  21. 21.
    Mauvais-Jarvis P. Current therapeutic data concerning mastodynia and benign mastopathy. Therapeutique 43:575, 1972.Google Scholar
  22. 22.
    Meyrick R.L., Smith I. Benign breast swelling. Br. Med. J. 2:585, 1972.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Colin C., Gaspard V., Lambotte R. Relationship of mastodynia with its endocrine envi-roment and treatment in a double blind trial with lyne-strol. Archiv. fur Gynaekologie 225: 7, 1978.CrossRefGoogle Scholar
  24. 24.
    Bradley D.D., Wingerd J., Petitti D.B. Serum high density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N. Engl. J. Med. 299:17, 1978.PubMedCrossRefGoogle Scholar
  25. 25.
    Hirnoven E., Malkonen M., Manninem V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N. Engl. J. Med. 304:560, 1981.CrossRefGoogle Scholar
  26. 26.
    Fahraeus L., Larsson-Cohn U., Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur. J. Clin. Invest. 30:447, 1983.CrossRefGoogle Scholar
  27. 27.
    Ottoson V.B., Johansson B.G., Von Schoultz B. Subtraction of high-density lipoprotein cholesterol during estrogen replacement therapy: comparison between progestogens and natural progesterone. Am. J. Obstet. Gynecol. 151: 746, 1985.CrossRefGoogle Scholar
  28. 28.
    McFadyen I.S., Raab G.M., Maclntyre C.C.A., Forrest A.P.M. Progesterone cream for cyclic breast pain. Br. Med. J. 298:931, 1989.CrossRefGoogle Scholar
  29. 29.
    Maxson W.B., Hargrove J.T. Bioavailability of oral micronized progesterone. Fertil. Steril. 44: 622, 1985.PubMedGoogle Scholar
  30. 30.
    Villaneuva B., Casper R.F., Yen S.S.C. Intravaginal administration of progesterone: enhanced after estrogen treatment. Fertil. Steril. 35:433, 1981.Google Scholar
  31. 31.
    Nappi C., Mercorio F., Affinito P., Lepore L., Montemagno U. Vaginal administration of natural progesterone in premenopausal women with endometrial hyperplasia. In: Genazzani A.R., Petraglia F. and Volpe A. (Eds.), Research Reports on Gynecology and Obstetrics. The Parthenon Publishing Group, Carnforth, 1989, p. 543.Google Scholar
  32. 32.
    Haagensen CD., Bodian C., Haagensen D.E.Jr. Fibrous disease of the breast. In: Breast carcinoma. Risk and detection. W.B. Saunders Company, Philadelphia, 1981, p. 132.Google Scholar
  33. 33.
    Hsueh A.J.W., Peck E.J., Clark J.H. Progesterone antagonism of the estrogen receptor and estrogen-induced uterine growth. Nature 254: 337, 1975.PubMedCrossRefGoogle Scholar
  34. 34.
    Tseng L., Gurpide E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 97: 825, 1975.PubMedCrossRefGoogle Scholar
  35. 35.
    Prudhomme J.F., Malet C., Gompel A., Lalardne J.P., Ochoa C., Boue A., Mauvais-Jarvis P., Kutten F. 17β-hydroxysteroid dehydrogenase (E2DH) activity in human breast epithelial cell and fibroblast cultures. Endocrinology 114:1483, 1984.CrossRefGoogle Scholar
  36. 36.
    Gompel A., Malet C., Spritzer P., Lalardrie J.P., Kutten F., Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab. 63:1174, 1986.PubMedCrossRefGoogle Scholar
  37. 37.
    Morville R., Dray F., Reyner J., Barrat J. Biodisponibilité de la progesterone naturelle admin-istrée par voie orale. Mésure des concentrations du stéroide dans le plasma, l’endomètre et le tissue mammaire. J. Gynecol. Obstet. Biol. Repr. 11:355, 1982.Google Scholar
  38. 38.
    Krause W., Wichmann U., Horn W. Resorption of progesterone through the intact skin of the breast in comparison with other body regions Geburtshilfe Frauenheilkd 47:562, 1987.PubMedCrossRefGoogle Scholar
  39. 39.
    Bucks D.A., McMaster J.R., Maibach H.I., Guy R.H. Biovailability of topically administered steroids: a “mass balance” technique. J. Invest. Dermatol. 91: 29, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1992

Authors and Affiliations

  • C. Nappi
    • 1
  • Pietro Affinito
    • 2
  • C. Di Carlo
    • 2
  • G. Esposito
    • 3
  • U. Montemagno
    • 2
  1. 1.Cattedra di Endocrinologia GinecologicaUniversità di TorinoTorinoItaly
  2. 2.Istituto di Ginecologia ed Ostetricia, II Facoltà di Medicina e ChirurgiaUniversità degli Studi di Napoli “Federico II”NapoliItaly
  3. 3.Angelini F., A.C.R.A.F.RomaItaly

Personalised recommendations